All In MedTech

Device Trial Radar · NCT06052956

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

A Phase 2 Study to Assess Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 15, 2027

Primary completion

Jun 30, 2032

Study completion Jun 30, 2032

Sponsor

Lead sponsor
University of RochesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 25, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) sham control + standard of care abscess drainage. The primary endpoint is time to removal of the drainage catheter.

Conditions

  • Abscess

Interventions

  • Methylene BlueDrug

    Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.

  • Lipid EmulsionDrug

    The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.

  • Insertion of optical fiberDevice

    A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.

  • Laser Illumination (pre-defined dose)Device

    Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.

  • Optical Spectroscopy MeasurementDevice

    The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.

  • Laser Illumination (patient-specific dose)Device

    Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.

  • Standard of care abscess drainageProcedure

    Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.

  • Inert blue dyeDrug

    Administration of inert, sterile, clinical-grade blue dye to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with clear, sterile saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to removal of the drainage catheterTime frame: Day 1 post-intervention until removal of drainage catheter

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Highland Hospital

    Rochester, New York

  • University of Rochester Medical Center

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.